BEEP tested an eczema prevention promise

A familiar treatment can acquire a second promise almost unnoticed. If moisturiser helps care for eczema-prone skin, perhaps applying it before eczema appears will stop the disease from starting. The Barrier Enhancement for Eczema Prevention study—BEEP—was designed to test that extra promise. Its research summary describes a plausible starting point: impaired skin-barrier function may precede eczema, and emollients help skin retain water.[1]

Plausibility made the experiment worth doing. It could not supply the result. Reading BEEP closely means keeping three questions apart: whether an intervention treats existing disease, whether it prevents disease, and how long any preventive effect lasts.

A caregiver rubs a baby's back as the baby lies on a bed. — Infant skin care. This photograph accompanied King's College London's February 2020 report on BEEP. The university does not identify the baby as a trial participant.[7]

Read the promise before the percentages

The Health Research Authority's study record describes a practical ambition: add daily moisturiser to ordinary infant skin-care advice and see whether fewer high-risk children develop eczema. It was a proposal for something families could do repeatedly at home, without a specialist procedure.[1]

That setting gives the question its force. A daily routine asks for time and attention even when it looks simple. Before making it preventive medicine, the benefit needs to appear in children's outcomes, rather than follow from how reassuring the routine feels.

The protocol published in July 2017 specified term infants with a first-degree relative who had eczema, asthma or allergic rhinitis. Randomisation took place within three weeks of birth. Both groups received skin-care advice; the intervention group also received emollients and instructions for daily application through the first birthday. Parents knew their allocation, while the planned assessment at age two was blinded.[2]

The calendar was part of the experiment. The primary assessment came a year after the prescribed intervention ended. This separates asking whether a regimen has a lasting preventive effect from asking how skin looks while that regimen is being used.[2]

A reader therefore needs more than the words moisturiser trial. The population, the added routine and the point of assessment define the promise being tested.

A small numerical gap was not proof of protection

The 2020 report described 1,394 randomised infants. Among children with primary outcome data, eczema meeting UK Working Party criteria for the preceding year, assessed at age two, occurred in 139 of 598 in the emollient group and 150 of 612 controls: about 23% versus 25%. The adjusted relative risk was 0.95, with a 95% confidence interval of 0.78–1.16.[3]

That interval matters more than the tempting subtraction of the rounded percentages. It spans possible benefit and harm; the trial did not establish prevention, but neither did it prove that the true effect must be exactly zero.

Safety also entered the balance. Parents reported an average of 0.23 skin infections per child during the first year in the intervention group, against 0.15 in controls; the adjusted incidence rate ratio was 1.55 (95% CI 1.15–2.09).[3] These are infection episodes per child, not the percentages of children infected. Keeping the unit attached prevents a safety signal from becoming a misleading headline.

Following children changes what can be claimed

The five-year follow-up, published online in November 2022 and in Allergy in 2023, did not reveal a delayed preventive benefit. Parents reported a clinical eczema diagnosis between 12 and 60 months for 31% of the emollient group and 28% of controls; the adjusted relative risk was 1.10 (95% CI 0.93–1.30).[4]

These later outcomes came from parental questionnaires reporting clinical diagnoses. They were not repeated blinded skin examinations. Follow-up extended the observation window while changing the way evidence was collected—a distinction that belongs beside the reassuring phrase long-term results.[4]

A later trial asks readers to compare the questions

In July 2025, the US CASCADE trial reported a different result. It randomised 1,247 infants without selecting only families at increased allergic risk. Daily emollient use continued through age two. Its primary outcome was cumulative clinician-diagnosed eczema documented in medical records: 36.1% versus 43.0%, a relative risk of 0.84 (95% CI 0.73–0.97).[5]

CASCADE thus changes the population, duration and outcome definition. Its percentages cannot be set directly against BEEP's as though both counted the same event over the same window. Nor did CASCADE's statistical test establish that family-risk status explained the difference in effects between its own subgroups.[5]

The studies make a blanket verdict difficult. Their differences identify questions for further work; they do not prove which difference produced the contrasting findings. BEEP remains evidence about the regimen it tested, while CASCADE prevents its negative result from closing every version of the prevention question.

The treatment question stays separate

NICE's guidance for children who already have atopic eczema identifies emollients as a foundation of management, including during periods when the eczema is clear.[6] That is a different clinical task from stopping a first diagnosis in a newborn.

BEEP therefore gives no basis for abandoning a child's prescribed eczema treatment. Equally, successful treatment cannot by itself validate a preventive routine for unaffected infants. The same product can occupy both questions, but evidence has to answer each one.

The durable lesson is a reading habit: keep the intended benefit attached to the people, regimen and outcome actually studied. A bottle may look unchanged. The claim being made for it can be entirely different.

cronfeed.work